Development of interstitial pneumonia during treatment with eribulin: a case report
| Autor: | Shigeru Tominaga, Shinichi Sasaki, Yosuke Miyashita, Kota Nakamura, Osamu Nagashima, Kazuhisa Takahashi, Motoyasu Kato |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Organized pneumonia Advanced breast medicine.medical_treatment lcsh:Medicine Case Reports General Biochemistry Genetics and Molecular Biology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Drug-induced lung toxicity medicine Humans Interstitial pneumonia Eribulin lcsh:Science (General) Furans lcsh:QH301-705.5 Chemotherapy Dry cough business.industry lcsh:R General Medicine Ketones Middle Aged medicine.disease Drug-induced interstitial pneumonia Surgery respiratory tract diseases 030104 developmental biology chemistry lcsh:Biology (General) 030220 oncology & carcinogenesis Heart failure Female Radiography Thoracic business Lung Diseases Interstitial Tomography X-Ray Computed Carbohydrate antigen lcsh:Q1-390 |
| Zdroj: | BMC Research Notes BMC Research Notes, Vol 10, Iss 1, Pp 1-4 (2017) |
| ISSN: | 1756-0500 |
| Popis: | Background Eribulin is typically used to treat patients with advanced breast cancer, and anti-cancer agents often cause the development of interstitial pneumonia in Japanese patients with advanced cancer. However, few case reports have addressed eribulin-induced interstitial pneumonia. Herein, we report a rare case of interstitial pneumonia—specifically, organized pneumonia—during treatment with eribulin in a patient with advanced breast cancer. Case presentation A 52-year-old Japanese woman was diagnosed as having advanced breast cancer 3 years before the admission described in the present report. She had received eribulin as third-line chemotherapy. Five days after her second treatment with eribulin, she was admitted to our hospital with dyspnea and dry cough. Upon admission, a chest computed tomography scan showed consolidation, with air bronchograms along the bronchovascular bundle of both lower lobes. The patient’s serum levels of sialylated carbohydrate antigen Krebs von den Lungen-6 were high, as were her surfactant protein-D levels. There was no evidence of heart failure, renal failure, or infection. Based on the clinical cause, as well as on the findings of organized pneumonia, the patient was diagnosed as having interstitial pneumonia and treated with corticosteroids. After the initiation of steroid treatment, her respiratory condition and chest radiological findings improved. Conclusions This case reveals an association between eribulin treatment and interstitial pneumonia. To our knowledge, this is the first case report to describe eribulin-induced organized pneumonia. Clinicians should be aware that interstitial pneumonia can develop during treatment with anti-cancer agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|